GT Biopharma (GTBP) had the highest return between March 5, 2017 and March 31, 2017 by a US stock, returning 5,888,081.8%.
| ASSET | DATE | % RETURN |
|---|---|---|
GT Biopharma (GTBP) | 3/5/2017 - 3/31/2017 | 5,888,081.82% |
OLB (OLB) | 3/5/2017 - 3/31/2017 | 200% |
TSS, Inc Common Stock (TSSI) | 3/5/2017 - 3/31/2017 | 106.96% |
Opus Genetics (IRD) | 3/5/2017 - 3/31/2017 | 104.9% |
VerifyMe (VRME) | 3/5/2017 - 3/31/2017 | 100% |
Ammo (POWW) | 3/5/2017 - 3/31/2017 | 80% |
Verastem (VSTM) | 3/5/2017 - 3/31/2017 | 78.45% |
GrabAGun Digital (PEW) | 3/5/2017 - 3/31/2017 | 72.35% |
Power Solutions International, Inc Common Stock (PSIX) | 3/5/2017 - 3/31/2017 | 71.02% |
Harrow Health (HROW) | 3/5/2017 - 3/31/2017 | 70.2% |
Catalyst Pharmaceuticals (CPRX) | 3/5/2017 - 3/31/2017 | 66.67% |
Akari Therapeutics (AKTX) | 3/5/2017 - 3/31/2017 | 66.47% |
Nektar Therapeutics (NKTR) | 3/5/2017 - 3/31/2017 | 60.97% |
Amneal Pharmaceuticals, Inc Class A Common Stock (AMRX) | 3/5/2017 - 3/31/2017 | 57.14% |
India Globalization Capital (IGC) | 3/5/2017 - 3/31/2017 | 56.67% |
Gyre Therapeutics (GYRE) | 3/5/2017 - 3/31/2017 | 56.64% |
Noodles (NDLS) | 3/5/2017 - 3/31/2017 | 55.41% |
Corvus Pharmaceuticals (CRVS) | 3/5/2017 - 3/31/2017 | 53.85% |
Cassava Sciences (SAVA) | 3/5/2017 - 3/31/2017 | 53.45% |
Filana Therapeutics (FLNA) | 3/5/2017 - 3/31/2017 | 53.45% |
XOMA (XOMA) | 3/5/2017 - 3/31/2017 | 51.28% |
Datasea (DTSS) | 3/5/2017 - 3/31/2017 | 51.25% |
Eterna Therapeutics (ERNA) | 3/5/2017 - 3/31/2017 | 50.88% |
Alterity Therapeutics (ATHE) | 3/5/2017 - 3/31/2017 | 49.76% |
RH (RH) | 3/5/2017 - 3/31/2017 | 48.22% |
